Bone Biologics Corp BBLG Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 17, 2024 (filed on Jan 19, 2024)

Insider Name:

Walsh Deina H

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--
Jan 17, 2024 (filed on Jan 19, 2024)

Insider Name:

Frelick Jeff

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

25,000

Price:

--
Jan 10, 2024 (filed on Jan 10, 2024)

Insider Name:

Gagnon Robert E.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 08, 2024 (filed on Jan 10, 2024)

Insider Name:

Gagnon Robert E.

Ownership Type:

Direct Ownership

Securities:

Non-Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8

Price:

--
Jan 08, 2024 (filed on Jan 10, 2024)

Insider Name:

Gagnon Robert E.

Ownership Type:

Direct Ownership

Securities:

Non-Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9

Price:

--
Sep 18, 2023 (filed on Sep 20, 2023)

Insider Name:

Lucera Erick

Ownership Type:

Direct Ownership

Securities:

Non-Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

85,763

Price:

--
Sep 18, 2023 (filed on Sep 20, 2023)

Insider Name:

Angle Siddhesh Rajendra

Ownership Type:

Direct Ownership

Securities:

Non-Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

85,763

Price:

--
Sep 18, 2023 (filed on Sep 20, 2023)

Insider Name:

Stroever Bruce

Ownership Type:

Direct Ownership

Securities:

Non-Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

85,763

Price:

--
Sep 13, 2023 (filed on Sep 14, 2023)

Insider Name:

Walsh Deina H

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

8,000

Price:

$0.64
Sep 11, 2023 (filed on Sep 12, 2023)

Insider Name:

Frelick Jeff

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

9,500

Price:

$0.69

Filings by filing date

Jan 17, 2024 (filed on Jan 19, 2024)

Insider Name:

Walsh Deina H

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--
Jan 17, 2024 (filed on Jan 19, 2024)

Insider Name:

Frelick Jeff

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

25,000

Price:

--
Jan 08, 2024 (filed on Jan 10, 2024)

Insider Name:

Gagnon Robert E.

Ownership Type:

Direct Ownership

Securities:

Non-Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8

Price:

--
Jan 08, 2024 (filed on Jan 10, 2024)

Insider Name:

Gagnon Robert E.

Ownership Type:

Direct Ownership

Securities:

Non-Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9

Price:

--
Jan 10, 2024 (filed on Jan 10, 2024)

Insider Name:

Gagnon Robert E.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Sep 18, 2023 (filed on Sep 20, 2023)

Insider Name:

Lucera Erick

Ownership Type:

Direct Ownership

Securities:

Non-Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

85,763

Price:

--
Sep 18, 2023 (filed on Sep 20, 2023)

Insider Name:

Angle Siddhesh Rajendra

Ownership Type:

Direct Ownership

Securities:

Non-Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

85,763

Price:

--
Sep 18, 2023 (filed on Sep 20, 2023)

Insider Name:

Stroever Bruce

Ownership Type:

Direct Ownership

Securities:

Non-Employee Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

85,763

Price:

--
Sep 13, 2023 (filed on Sep 14, 2023)

Insider Name:

Walsh Deina H

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

8,000

Price:

$0.64
Sep 11, 2023 (filed on Sep 12, 2023)

Insider Name:

Frelick Jeff

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

9,500

Price:

$0.69

News

Biz Brief

Sector: Healthcare	Industry: Medical Equipment, Supplies & Distribution

See Regulatory Filings on SEC

Company Contact

Address:	2 Burlington Woods Dr Ste 100 BURLINGTON MA 01803-4551
Tel:	1-212-8383777
Website:	https://www.bonebiologics.com
IR:	See website

Key People

Don Hankey Chairman of the Board	Jeffrey Frelick President, Chief Executive Officer	Deina H. Walsh Chief Financial Officer

Business Overview

Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

Financial Overview

For the fiscal year ended 31 December 2023, Bone Biologics Corp revenues was not reported. Net loss increased from $1.5M to $8.9M. Higher net loss reflects Research and development increase from $1.6M to $6.9M (expense), Change in fair value of warrant liabilit decrease of 69% to $893K (income), General and administrative increase of 21% to $2.5M (expense).

Employees:	2 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	N/A
Annual revenue (TTM):	$0.00M as of Dec 31, 2023
EBITDA (TTM):	-$9.43M as of Dec 31, 2023
Net annual income (TTM):	-$8.95M as of Dec 31, 2023
Free cash flow (TTM):	-$9.56M as of Dec 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	879,176 as of Mar 6, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization